Spexis
Spexis
SPEX
SIX
0.04
CHF
0.00%
About
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 0 |
| Three Month Average Volume | 5.1M |
| High Low | |
| Fifty-Two Week High | 1.06 CHF |
| Fifty-Two Week Low | 0.0122 CHF |
| Fifty-Two Week High Date | 22 Jan 2024 |
| Fifty-Two Week Low Date | 14 Nov 2023 |
| Price and Volume | |
| Current Price | 0.057 CHF |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -7.29% |
| Thirteen Week Relative Price Change | -11.06% |
| Twenty-Six Week Relative Price Change | -64.50% |
| Fifty-Two Week Relative Price Change | -86.30% |
| Year-to-Date Relative Price Change | 24.36% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -7.77% |
| Twenty-Six Week Price Change | -61.49% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -84.59% |
| Year-to-Date Price Change | 39.02% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.0546 CHF |
| Book Value Per Share (Most Recent Quarter) | -0.0546 CHF |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.12159 CHF |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.12159 CHF |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.37081 CHF |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 CHF |
| Revenue Per Share (Trailing Twelve Months) | 0 CHF |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 CHF |
| Dividend Per Share (Trailing Twelve Months) | 0 CHF |
| Dividend Per Share (5 Year) | -99999.99 CHF |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.37008 CHF |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.35969 CHF |
| Normalized (Last Fiscal Year) | -0.15253 CHF |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.37008 CHF |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.35969 CHF |
| Including Extraordinary Items (Last Fiscal Year) | -0.37008 CHF |
| Including Extraordinary Items (Trailing Twelve Months) | -0.35969 CHF |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.00824 CHF |
| Cash Per Share (Most Recent Quarter) | 0.00824 CHF |
| Cash Flow Per Share (Last Fiscal Year) | -0.35324 CHF |
| Cash Flow Per Share (Trailing Twelve Months) | -0.35324 CHF |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.10338 CHF |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -822 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -1,117.43% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -1,055.30% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -1,117.43% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 25.07% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -59.31% |
| EPS Change (Trailing Twelve Months) | 6.60% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 7.4M |
| Net Debt (Last Fiscal Year) | 7.4M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 1 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 1 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,480,530 |
| Free Cash Flow (Trailing Twelve Months) | -5,480,530 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -84.79% |
| Return on Assets (Trailing Twelve Months) | -84.79% |
| Return on Assets (5 Year) | -53.28% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -242.47% |
| Return on Equity (Trailing Twelve Months) | -242.47% |
| Return on Equity (5 Year) | -90.28% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -149.58% |
| Return on Investment (Trailing Twelve Months) | -149.58% |
| Return on Investment (5 Year) | -68.93% |